White Paper

Is Your CMO Ready For Serialization And Aggregation?

Source: AbbVie

By Lloyd Mager

In the continuous improvement environment of pharmaceutical development and manufacturing, efforts to secure and enhance the supply chain include serialization and aggregation to exert more control over packaging, shipping, and distribution to enable traceability of finished drug products.

The U.S. Food and Drug Administration is halfway through its 10-year period to establish “an interoperable, electronic product tracing system at the package level” as part of the Drug Supply Chain Security Act (DSCSA). The purpose of the 2013 act is to identify suspect or illegitimate products in the supply chain, while also enabling manufacturers to notify FDA of any potentially dangerous products in supply.

Most recently, in February 2018, as part of DSCSA, FDA issued draft guidance on standards for the “interoperable exchange of transaction information, transaction history and transaction statements (product tracing information)” among trading partners. These exchanges must be electronic-only by 2023.

“With a dedicated traceability operation within the company, and serialization efforts in place, AbbVie has prepared a long-term strategy to address aggregation.”

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma